Equities research analysts expect that Phibro Animal Health Corp (NASDAQ:PAHC) will post earnings of $0.42 per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Phibro Animal Health’s earnings. The highest EPS estimate is $0.44 and the lowest is $0.40. Phibro Animal Health posted earnings of $0.38 per share during the same quarter last year, which would indicate a positive year over year growth rate of 10.5%. The firm is scheduled to report its next earnings results after the market closes on Tuesday, November 6th.
On average, analysts expect that Phibro Animal Health will report full-year earnings of $1.75 per share for the current fiscal year, with EPS estimates ranging from $1.73 to $1.77. For the next year, analysts expect that the company will report earnings of $1.87 per share, with EPS estimates ranging from $1.84 to $1.90. Zacks’ EPS averages are an average based on a survey of sell-side research firms that follow Phibro Animal Health.
Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings data on Monday, August 27th. The company reported $0.46 EPS for the quarter, topping the consensus estimate of $0.42 by $0.04. The firm had revenue of $211.80 million during the quarter, compared to the consensus estimate of $209.27 million. Phibro Animal Health had a return on equity of 39.81% and a net margin of 7.90%. The company’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.39 earnings per share.
Several analysts have recently commented on the company. BidaskClub downgraded Phibro Animal Health from a “buy” rating to a “hold” rating in a research note on Thursday, August 16th. Zacks Investment Research downgraded Phibro Animal Health from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 24th. Finally, Morgan Stanley increased their price objective on Phibro Animal Health from $36.00 to $46.00 and gave the stock an “underweight” rating in a research note on Wednesday, August 29th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $43.20.
Shares of Phibro Animal Health stock traded down $0.20 on Tuesday, hitting $42.18. The company had a trading volume of 82,909 shares, compared to its average volume of 111,820. The company has a market cap of $1.71 billion, a PE ratio of 24.24, a price-to-earnings-growth ratio of 3.55 and a beta of 0.82. Phibro Animal Health has a 1 year low of $32.05 and a 1 year high of $54.62. The company has a quick ratio of 1.66, a current ratio of 2.90 and a debt-to-equity ratio of 1.62.
In other news, VP Daniel M. Bendheim sold 2,500 shares of the stock in a transaction that occurred on Wednesday, September 12th. The stock was sold at an average price of $44.30, for a total value of $110,750.00. Following the completion of the sale, the vice president now directly owns 2,500 shares of the company’s stock, valued at $110,750. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Jack Bendheim sold 30,000 shares of the stock in a transaction that occurred on Wednesday, August 8th. The stock was sold at an average price of $50.20, for a total value of $1,506,000.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 183,020 shares of company stock valued at $8,971,771. Company insiders own 50.29% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in PAHC. Royal Bank of Canada grew its holdings in shares of Phibro Animal Health by 2,104.6% in the first quarter. Royal Bank of Canada now owns 3,814 shares of the company’s stock valued at $151,000 after acquiring an additional 3,641 shares in the last quarter. Meeder Asset Management Inc. grew its holdings in shares of Phibro Animal Health by 149.2% in the second quarter. Meeder Asset Management Inc. now owns 4,470 shares of the company’s stock valued at $206,000 after acquiring an additional 2,676 shares in the last quarter. Piedmont Investment Advisors LLC bought a new position in shares of Phibro Animal Health in the second quarter valued at approximately $213,000. Janus Henderson Group PLC bought a new position in shares of Phibro Animal Health in the second quarter valued at approximately $222,000. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Phibro Animal Health in the second quarter valued at approximately $255,000. 47.95% of the stock is owned by institutional investors.
About Phibro Animal Health
Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture.
Further Reading: What does cost of debt say about a company’s financial health?
Get a free copy of the Zacks research report on Phibro Animal Health (PAHC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.